3SBio (1530) AI Stock Analysis

• Market Cap: HK$72.95B
• Dividend Yield: 0.03%
• Average Volume (3M): 41.79M
• Price to Earnings (P/E): 30.5
• Beta (1Y): 0.98
• Revenue Growth: 14.36%
• EPS Growth: 33.22%
• Country: HK
• Employees: 5,577
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): 0.46
• Shares Outstanding: 2,399,586,400
• 10 Day Avg. Volume: 44,561,928
• 30 Day Avg. Volume: 41,789,526
• PEG Ratio: 1.00
• Price to Book (P/B): 3.35
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 57.32
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$24.10
• Price Target Upside: -20.73% Downside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 69 Neutral
• Price Target: HK$31.00 ▲(1.97%Upside)

The overall stock score of 69 reflects 3SBio's solid financial performance and strong technical momentum. However, the high valuation and overbought technical indicators suggest caution. Financial performance is the most significant factor, supported by revenue growth and balance sheet stability, but investors should be mindful of valuation concerns.

Positive Factors

Product Performance

TPIAO's sales increased 20.4% YoY to RMB5.1bn, becoming the leading drug in China's thrombocytopenia treatment market, with stable pricing and increasing penetration.

Revenue Growth

3SBio delivered a strong performance with revenue increasing 16.5% YoY to RMB9.1bn, driven by the robust growth of TPIAO, Mandi and other products.

Strategic Expansion

3SBio has expanded its pipeline through strategic in-licensing, acquiring four key assets, including Paclitaxel Oral Solution which has received NMPA approval.

Negative Factors

Dividend Payout

3SBio has declared a final dividend of HK$0.25/shares, for a payout ratio of ~29%.

3SBio Business Overview & Revenue Model

Company Description

3SBio Inc. is a leading biopharmaceutical company in China, specializing in the research, development, manufacturing, and commercialization of biopharmaceutical products. The company primarily focuses on providing therapies in oncology, nephrology, and autoimmune diseases. It offers a range of products, including recombinant human erythropoietin, recombinant human thrombopoietin, and other biologics, catering to the growing healthcare needs in China and select international markets.

How the Company Makes Money

3SBio generates revenue through the sale of its biopharmaceutical products, particularly in the areas of oncology, nephrology, and autoimmune diseases. The company's revenue streams are primarily derived from its proprietary drugs, which include a portfolio of biologics such as recombinant human erythropoietin and thrombopoietin. Additionally, 3SBio engages in strategic partnerships and collaborations with other pharmaceutical companies to expand its product offerings and market reach. The company also invests in research and development to innovate and introduce new therapeutic solutions, which contribute to its long-term revenue growth.

3SBio Financial Statement Overview

Summary

3SBio demonstrates robust financial health with strong revenue and profit growth, solid balance sheet stability, and effective cash management. However, cash flow consistency needs improvement due to fluctuating capital expenditures and investing cash flows.

Income Statement

3SBio shows a strong income statement with consistent revenue growth from 2019 to 2024. The gross profit margin is robust, indicating efficient cost management, and the net profit margin has improved significantly over the years, demonstrating enhanced profitability. The EBIT and EBITDA margins are healthy, showcasing strong operational performance.

Balance Sheet

The balance sheet reflects a solid equity base with a decreasing debt-to-equity ratio over the years, signaling improved financial stability. Return on Equity (ROE) is strong, indicating effective utilization of equity. The equity ratio indicates a sound proportion of assets funded by equity, although the increase in total liabilities in recent years suggests a need for cautious financial management.

Cash Flow

Cash flow from operations has been positive, reflecting good cash management and business operations. However, the free cash flow growth is inconsistent due to fluctuating capital expenditures and investing cash flows, which may pose a risk to liquidity. The operating cash flow to net income ratio indicates healthy cash conversion, but the absence of 2024 cash flow data limits full analysis.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.11B	7.82B	6.86B	6.38B	5.59B
Gross Profit	7.83B	6.64B	5.67B	5.28B	4.52B
EBITDA	2.93B	2.53B	2.75B	2.26B	1.59B
Net Income	2.09B	1.55B	1.92B	1.65B	835.79M
Balance Sheet
Total Assets	24.21B	23.63B	21.99B	19.21B	17.68B
Cash, Cash Equivalents and Short-Term Investments	5.79B	5.99B	7.01B	4.70B	4.36B
Total Debt	3.55B	4.84B	4.47B	2.63B	2.91B
Total Liabilities	6.18B	7.11B	6.59B	4.55B	4.58B
Stockholders Equity	15.44B	14.03B	12.96B	12.23B	10.69B
Cash Flow
Free Cash Flow	2.24B	1.38B	1.21B	432.57M	363.09M
Operating Cash Flow	3.20B	2.08B	2.18B	1.58B	1.34B
Investing Cash Flow	-1.36B	-1.35B	-3.72B	-1.29B	-1.87B
Financing Cash Flow	-2.25B	-352.98M	714.91M	-481.12M	1.55B

3SBio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 30.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1530, the sentiment is Positive. The current price of 30.4 is above the 20-day moving average (MA) of 26.38, above the 50-day MA of 22.49, and above the 200-day MA of 11.39, indicating a bullish trend. The MACD of 2.31 indicates Negative momentum. The RSI at 69.13 is Neutral, neither overbought nor oversold. The STOCH value of 67.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1530.

3SBio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2269	77 Outperform	HK$121.46B	33.67	8.17%	―	7.52%	-1.92%
2696	72 Outperform	HK$33.70B	37.88	31.65%	―	4.23%	47.71%
1530	69 Neutral	HK$72.95B	30.53	14.19%	0.03%	14.36%	33.22%
1177	68 Neutral	HK$120.01B	63.05	6.14%	0.20%	7.63%	-24.23%
Sector *	65 Neutral	¥355.44B	11.10	-2.99%	2.49%	11.76%	-10.16%
1801	61 Neutral	$149.75B	―	-0.72%	―	49.33%	90.96%
1877	59 Neutral	HK$37.94B	―	-19.78%	―	25.96%	39.58%

3SBio Corporate Events

3SBio and Pfizer Finalize License Agreement and Share Subscription

3SBio, a biopharmaceutical company, has announced that its License Agreement with Pfizer for the PD-1/VEGF bispecific antibody (SSGJ-707) has come into effect, allowing Pfizer an exclusive option to develop and commercialize the product in China. Additionally, Pfizer has agreed to subscribe to new shares of 3SBio, representing a 1.28% stake post-issuance, at a discounted price, raising approximately HK$785.0 million for 3SBio.

The most recent analyst rating on (HK:1530) stock is a Hold with a HK$25.81 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.

3SBio Inc. Announces AGM Results, Dividend Payment, and Committee Changes

3SBio Inc. announced the results of its Annual General Meeting (AGM) held on June 25, 2025, where all proposed resolutions were passed by poll. The company also declared a final dividend payment and announced changes to its Nomination Committee. These developments are likely to impact the company’s governance structure and shareholder returns, potentially strengthening its position in the biotechnology sector.

The most recent analyst rating on (HK:1530) stock is a Buy with a HK$9.46 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.

3SBio Announces Board Roles and Functions

3SBio Inc., a company incorporated in the Cayman Islands, has announced the roles and functions of its board of directors and board committees. The announcement details the positions of executive, non-executive, and independent non-executive directors within the audit, nomination, and remuneration committees. This update is crucial for stakeholders to understand the governance structure and leadership dynamics within 3SBio, potentially impacting the company’s strategic direction and decision-making processes.

The most recent analyst rating on (HK:1530) stock is a Buy with a HK$9.46 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.

3SBio Inc. Updates Nomination Committee Terms of Reference

3SBio Inc. has outlined the terms of reference for its Nomination Committee, which is responsible for identifying and recommending suitable candidates for the company’s board of directors. The committee, comprising a majority of independent non-executive directors, plays a crucial role in overseeing board performance evaluations and developing nomination guidelines, thereby impacting the company’s governance and strategic direction.

The most recent analyst rating on (HK:1530) stock is a Buy with a HK$9.46 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.

3SBio Inc. Announces Annual General Meeting with Key Resolutions

3SBio Inc. has announced its upcoming annual general meeting scheduled for June 25, 2025, in Shenyang, China. Key agenda items include the adoption of the 2024 financial statements, re-election of directors, declaration of a final dividend, and re-appointment of auditors. The meeting will also address resolutions related to the issuance of additional shares, which could impact the company’s capital structure and shareholder value.

The most recent analyst rating on (HK:1530) stock is a Buy with a HK$9.46 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.

3SBio Partners with Pfizer for Global Licensing of Oncology Antibody

3SBio, Inc. has entered into an exclusive licensing agreement with Pfizer for its PD-1/VEGF bispecific antibody, SSGJ-707, granting Pfizer rights to develop, manufacture, and commercialize the product worldwide, excluding mainland China. This agreement includes an upfront payment of $1.25 billion to 3SBio, with potential additional payments up to $4.8 billion, and positions 3SBio strategically in the global oncology market, enhancing its industry standing and providing significant financial benefits.

The most recent analyst rating on (HK:1530) stock is a Buy with a HK$9.46 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.